Evidence map›Paper›PMID 31056733›Full record

Trial reportHeart and vessels2019

Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness.

Sangmo Hong, Munsuk Nam, Bertis B Little, Seihyun Paik, Kwanwoo Lee, Jungtaek Woo, Dooman Kim, Jungoo Kang, Minyoung Chun, Yongsoo Park

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Heart and vessels, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 2 countries.

Sangmo HongDivision of Endocrinology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Gyeonggi-do, South Korea.
Munsuk NamDepartment of Internal Medicine, Inha University School of Medicine, Incheon, South Korea.
Bertis B LittleBertis B. Little, Department of Health Management and Systems Sciences, University of Louisville, Louisville, KY, USA.
Seihyun PaikDivision of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, South Korea.
Kwanwoo LeeDepartment of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, South Korea.
Jungtaek WooDepartment of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, South Korea.
Dooman KimDepartment of Endocrinology and Metabolism, Hallym University School of Medicine, Seoul, South Korea.
Jungoo KangDepartment of Endocrinology and Metabolism, Hallym University School of Medicine, Seoul, South Korea.
Minyoung ChunDepartment of Global Medical Science, Sungshin Women's University, Seoul, South Korea.
Yongsoo ParkDepartment of Internal Medicine and Bioengineering, Hanyang University College of Medicine and Engineering, Seoul, South Korea. parkys60@gmail.com.ORCID http://orcid.org/0000-0003-3203-6780
Hallym University · KRAjou University · KRHallym University Dongtan Sacred Heart Hospital · KRHealth Insurance Review and Assessment Service · KRInha University · KRKorea University · KRKyung Hee University · KRSungshin Women's University · KRUniversity of Louisville · US

Funding

Ministry of Health and Welfare A102065
6 · The paper itself

Abstract

Antiplatelet drugs are effective in preventing recurrence of atherosclerosis in type 2 diabetes (T2D) patients. However, the efficacy and usefulness of antiplatelet drugs on the progression of carotid intima-media thickness (IMT), a marker for evaluating early atherosclerotic vascular disease, has not been analyzed. We conducted a prospective, randomized, open, 36-month trial comparing cilostazol vs. aspirin. A total of 415 T2D patients (age range 38-83 years; 206 females) without macrovascular complications were randomized to either an aspirin (100 mg/day) or cilostazol (200 mg/day) treatment. Patients underwent B-mode ultrasonography annually to assess the IMT and serum levels of inflammatory markers were measured before and after each treatment. Potential confounders were statistically adjusted, and included lipid profiles, HbA1c, body mass index, waist circumference, anti-hypertensive and statin medications. The decrease in mean left, maximum left, mean right and maximum right IMT were significantly greater with cilostazol compared with aspirin (- 0.094 ± 0.186 mm vs. 0.006 ± 0.220 mm, p < 0.001; - 0.080 ± 0.214 mm vs. 0.040 ± 0.264 mm, p < 0.001; - 0.064 ± 0.183 mm vs. 0.004 ± 0.203 mm, p = 0.015; - 0.058 ± 0.225 mm vs. 0.023 ± 0.248 mm, p = 0.022, respectively). And these differences remained significant after adjustment of potential confounders. Compared with aspirin, cilostazol treatment was associated with significantly increased HDL cholesterol (p = 0.039) and 25-hydroxy vitamin D levels (p = 0.001). Cilostazol treatment was associated with significantly lowered IMT in T2D patients compared to aspirin, independent of conventional cardiovascular risk factors. Cilostazol may inhibit plaque formation and have beneficial effects on atherosclerosis through vasodilatory and antiplatelet effects.

Indexed as

Carotid Intima-Media ThicknessAdultAgedAged, 80 and overAspirinAtherosclerosisCilostazolDiabetes Mellitus, Type 2Disease ProgressionDose-Response Relationship, DrugFemaleFollow-Up StudiesHumansMaleMiddle AgedPhosphodiesterase 3 InhibitorsAspirinCilostazolPhosphodiesterase 3 InhibitorsPlatelet Aggregation InhibitorsAnti-plateletAspirinCardiovascular disease (CVD)Carotid IMTCilostazolType 2 Diabetes

Identifiers

PMID31056733
OpenAlexW2943223234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.